ISDA: 4Y8Z

Deposition Date 2015-02-16

Release Date 2015-05-27

Last Version Date 2024-10-30

Entry Detail

PDB ID:

4Y8Z

Keywords:

HYDROLASE/HYDROLASE INHIBITOR

Title:

Factor XIa in complex with the inhibitor (2E)-N-[(1S)-1-[5-chloro-4-(4-hydroxy-2-oxo-1,2-dihydroquinolin-6-yl)-1H-imidazol-2-yl]-3-(4-methylpiperazin-1-yl)-3-oxopropyl]-3-[5-chloro-2-(1H-tetrazol-1-yl)phenyl]prop-2-enamide

Biological Source:

Source Organism:

Homo sapiens (Taxon ID: 9606)

Host Organism:

Escherichia coli BL21(DE3)

Method Details:

Experimental Method:

X-RAY DIFFRACTION

Resolution:

2.20 Å

R-Value Free:

0.26

R-Value Work:

0.23

R-Value Observed:

0.24

Space Group:

P 32 2 1

Download Validation Report

Macromolecular Entities

Structures with similar UniProt ID

Protein Blast

Polymer Type:polypeptide(L)
Molecule:Coagulation factor XIa
Gene (Uniprot):F11
Chain IDs:A
Chain Length:244
Number of Molecules:1
Biological Source:Homo sapiens

UniProt ID:P03951 Pfam ID:PF00089 EC:3.4.21.27

Ligand Molecules

4CE

EDO

SO4

Primary Citation

Discovery of a Potent Parenterally Administered Factor XIa Inhibitor with Hydroxyquinolin-2(1H)-one as the P2' Moiety.

Hu, Z, Wong, P.C, Gilligan, P.J, Han, W, Pabbisetty, K.B, Bozarth, J.M, Crain, E.J, Harper, T, Luettgen, J.M, Myers, J.E, Ramamurthy, V, Rossi, K.A, Sheriff, S, Watson, C.A, Wei, A, Zheng, J.J, Seiffert, D.A, Wexler, R.R, Quan, M.L, Quan, M.L, Wong, P.C, Wang, C, Woerner, F, Smallheer, J.M, Barbera, F.A, Bozarth, J.M, Brown, R.L, Harpel, M.R, Luettgen, J.M, Morin, P.E, Peterson, T, Ramamurthy, V, Rendina, A.R, Rossi, K.A, Watson, C.A, Wei, A, Zhang, G, Seiffert, D, Wexler, R.R, Hangeland, J.J, Friends, T.J, Rossi, K.A, Smallheer, J.M, Wang, C, Sun, Z, Corte, J.R, Fang, T, Wong, P.C, Rendina, A.R, Barbera, F.A, Bozarth, J.M, Luettgen, J.M, Watson, C.A, Zhang, G, Wei, A, Ramamurthy, V, Morin, P.E, Bisacchi, G.S, Subramaniam, S, Arunachalam, P, Mathur, A, Seiffert, D.A, Wexler, R.R, Quan, M.L, Corte, J.R, Fang, T, Hangeland, J.J, Friends, T.J, Rendina, A.R, Luettgen, J.M, Bozarth, J.M, Barbera, F.A, Rossi, K.A, Wei, A, Ramamurthy, V, Morin, P.E, Seiffert, D.A, Wexler, R.R, Quan, M.L, Pinto, D.J, Smallheer, J.M, Corte, J.R, Austin, E.J, Wang, C, Fang, T, Smith, L.M, Rossi, K.A, Rendina, A.R, Bozarth, J.M, Zhang, G, Wei, A, Ramamurthy, V, Sheriff, S, Myers, J.E, Morin, P.E, Luettgen, J.M, Seiffert, D.A, Quan, M.L, Wexler, R.R.Show

ACS Med Chem Lett 6 590 595 (2015)

PMID: 26005539 DOI: 10.1021/acsmedchemlett.5b00066

Abstact

Structure-activity relationship optimization of phenylalanine P1' and P2' regions with a phenylimidazole core resulted in a series of potent FXIa inhibitors. Introducing 4-hydroxyquinolin-2-one as the P2' group enhanced FXIa affinity and metabolic stability. Incorporation of an N-methyl piperazine amide group to replace the phenylalanine improved both FXIa potency and aqueous solubility. Combination of the optimization led to the discovery of FXIa inhibitor 13 with a FXIa K i of 0.04 nM and an aPTT EC2x of 1.0 μM. Dose-dependent efficacy (EC50 of 0.53 μM) was achieved in the rabbit ECAT model with minimal bleeding time prolongation.

Legend

Protein

Chemical

Disease

Primary Citation of related structures

Abstact

Feedback Form